The Shiseido Beauty Innovations Fund, established by the Chinese subsidiary of Shiseido Company, Limited ("Shiseido"), Shiseido China Co., Ltd. and Boyu Capital, announces its first investment in Jiangsu Trautec Medical Technology Co., Ltd. (Trautec). Shiseido will be the main investor with an investment of nearly RMB 100 million. In addition, Shiseido will form a strategic partnership with Trautec to work together in areas such as product R&D, raw material sourcing and sales channels to accelerate the exploration of new areas in functional skin care.
Founded in 2015, Trautec is dedicated to the development and production of recombinant collagen-based biomaterials for the primarily medical and cosmetic industries. As an industry pioneer, Trautec operates the complete value chain, from R＆D to distribution, holding multiple intellectual property rights to the development of recombinant collagen, and owning its production plant located in Changzhou, Jiangsu province. The functional skin care market is experiencing significant growth as more and more Chinese consumers seek effective solutions to their skin problems. The need for recombinant collagen is growing due to its stability and efficacy, as well as its wide application in medicine, healthcare and cosmetics.
The Shiseido Beauty Innovations Fund explores investment opportunities among emerging Chinese cosmetics and wellness companies, as well as related technology businesses such as e-commerce and digital services. Through this fund, Shiseido will merge its own values with those of emerging companies to enhance its business portfolio in China, meet the diversified needs of consumers and steadily strengthen business in China, which is one of the pillars of the company's medium- to long-term strategy "WIN 2023 and Beyond".
